Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
NCT03708224
Recruiting
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: University of San Francisco, California, San Francisco, California
Conditions: Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
Register for Updates
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
NCT04975555
Recruiting
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia
Register for Updates
Niclosamide in Pediatric Patients With Relapsed and Refractory AML
NCT05188170
Recruiting
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
01/24/2025
Locations: Stanford University, Palo Alto, California
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
NCT05757570
Recruiting
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Investigational Site (230), Los Angeles, California +43 locations
Conditions: Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Register for Updates
Intratumoral PH-762 for Cutaneous Carcinoma
NCT06014086
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +4 locations
Conditions: Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
Register for Updates
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
NCT06260774
Recruiting
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/24/2025
Locations: Mary Crowley Cancer Center, Dallas, Texas +3 locations
Conditions: Advanced Solid Tumor
Register for Updates
Post-Operative Thoracolumosacral Orthosis for PJK
NCT06491030
Recruiting
Proximal junctional kyphosis (PJK) is a common post-operative radiographic finding after surgery for adult spinal deformity (ASD) patients. Although the clinical relevance of isolated PJK is unclear, PJK can progress to symptomatic proximal junctional failures which requires a large revision surgery. Currently, post-operative bracing with a thoracolumbosacral orthosis (TLSO) is common practice after spinal deformity surgery, however the efficacy of this in preventing PJK is unknown. This multi-c... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
01/24/2025
Locations: Indiana Spine Group, Carmel, Indiana +5 locations
Conditions: Proximal Junctional Kyphosis, Adult Spinal Deformity Surgery, Thoracolumbosacral Orthosis
Register for Updates
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/24/2025
Locations: Northwestern University, Chicago, Illinois +16 locations
Conditions: Scleroderma, Diffuse
Register for Updates
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
NCT01999361
Recruiting
This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/24/2025
Locations: Diabetes Research Institute, Miami, Florida
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT03769415
Recruiting
The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is not known if this information is helpful in determining treatment when breast cancer has become metastatic. HARMONY will give the treating physician of each participant the molecular subtype of the tu... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/24/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +1 locations
Conditions: Breast Cancer
Register for Updates
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT04563507
Recruiting
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
01/24/2025
Locations: Weill Cornell Medicine, New York, New York +2 locations
Conditions: Breast Cancer
Register for Updates
The Impact of COVID-19 on Pulmonary Procedures
NCT05022446
Recruiting
This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.
Gender:
ALL
Ages:
All
Trial Updated:
01/24/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates